Press Releases GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 10:51:58 2026-02-18 EST			5-day change	1st Jan Change
2,270.50 ^GBX	+1.41%		+5.42%	+24.23%

10:32am	GSK plc Announces New Effectiveness Data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) At RSVVW'26	CI
02-17	The Jackson Laboratory-New York Stem Cell Foundation Collaborative and Gsk Announce Collaboration to Advance Translational Models for Neurodegenerative Disease Research	CI

Press Releases

08:01am	GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows	BU
06:45am	GSK plc - Exdensur approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps	AQ
02-17	GSK : Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows	PU
02-10	GSK : RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older	PU
02-05	GSK : FY 2025 results transcript	PU
02-04	Glaxo: Q4 Earnings Snapshot	AQ
02-04	GSK : Full results	PU
02-04	GSK : FY 2025 results slides	PU
02-04	GSK : FY 2025 pipeline assets and clinical trials report	PU
02-04	GSK : FY 2025 results infographic	PU
02-04	GSK : FY 2025 US dollar translation	PU
02-04	GSK : delivers strong 2025 performance and re-affirms long-term outlooks	PU
01-26	GSK : RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older	PU
01-23	GSK : Trelegy Ellipta approved in China for use in adults with uncontrolled asthma	PU
01-21	GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026	BU
01-21	GSK enters agreement to acquire RAPT Therapeutics	AQ
01-20	GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million	BU
01-20	GSK : Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding	PU
01-14	GSK : Q4 2025 pre announcement aide memoire	PU
01-07	GSK : Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission	PU
01-07	GSK : announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B	PU
12-19	GSK : enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans	PU
12-19	GSK : CBCR data 2024	PU
12-17	GSK plc - Exdensur approved by US FDA for the treatment of severe asthma	AQ
12-16	Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma	BU